Table III.
Summary of the literature data on VWF:RCo pharmacology results in VWD patients treated with Haemate P
| Median (range) | ||||
|---|---|---|---|---|
|
| ||||
| N | t1/2 (hours) | Classical IVR (%) | Incremental IVR (IU/dL)/(IU/kg) | |
| Mannucci et al.22 | 10 | 2.2 (0.6) | ||
| CSL study: 20123 | 10 | 10.3 (6.4–18.6) | 71.0 (50.0–96.0) | 1.9 (1.1–2.7) |
| CSL study: A400112,20 | 8 | 6.8 (1.4–13.3) | ||
| Bleeding arm | 7 | 1.5 (0.6–1.8) | ||
| Surgery arm | 7 | 1.7 (0.5–2.6) | ||
| Prophylaxis arm | 3 | 0.8 (0.7–1.5) | ||
| Franchini et al.11 | 26 | 2.0 (1.4–2.7) | ||
| Michiels et al.24 | 5 | ~12(>1–16) | 1.7(1.4–2.1) | |
| CSL study: B400115,21 | 28 | 9.9 (2.8–51.1) | 73.6 (24.5–180.3) | 1.9 (0.6–4.5) |
Note: t1/2 was generally calculated as part of a two-compartment, elimination-phase t1/2 model. Classical in vivo recovery (IVR) describes the observed peak activity in relation to the expected peak activity. The incremental IVR indicates the IU/dL activity rise in plasma per IU/kg body weight infused.